Related Experiment Video
Updated: May 17, 2026
10:28
Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats
Published on: December 5, 2017
Genetic-based reference values for angiotensin-converting enzyme (ACE) according to I/D polymorphism in a Spanish
Silvia Camós1, M Jesús Cruz, Ferran Morell
1Laboratoris Clinics, Servei de Bioquímica Clínica, Hospital Universitari Vall d’Hebron, Barcelona, Spain.
Clinical Chemistry and Laboratory Medicine
|October 24, 2012
Summary
Serum angiotensin-converting enzyme (ACE) activity reference values vary significantly by ACE gene I/D polymorphism in Spanish individuals. These findings aid in diagnosing and monitoring granulomatous diseases like sarcoidosis.
Area of Science:
- Genetics and Molecular Biology
- Clinical Biochemistry
- Immunology
Background:
- Serum angiotensin-converting enzyme (ACE) activity is linked to granulomatous diseases, including sarcoidosis.
- ACE gene I/D polymorphism influences serum ACE activity levels.
- Establishing genotype-specific reference values is crucial for improved diagnostic sensitivity and treatment monitoring.
Purpose of the Study:
- To determine reference values for serum ACE activity based on ACE gene I/D polymorphism in a Spanish population.
- To provide a basis for more accurate diagnosis and monitoring of sarcoidosis and related conditions.
Main Methods:
- Serum ACE activity and ACE gene I/D polymorphism were analyzed in 150 healthy Spanish blood donors.
- Reference intervals were calculated as the 95% central range (2.5th-97.5th percentiles) for each genotype (DD, DI, II) and the overall sample.
Main Results:
- Genotype frequencies: DD (37%), DI (43%), II (20%).
- Mean ACE activity: DD (39.0 U/L), DI (29.5 U/L), II (19.1 U/L), with significant differences between groups (p<0.05).
- Reference intervals varied by genotype: DD (12.3-65.6 U/L), DI (9.5-49.5 U/L), II (9.6-28.7 U/L).
Conclusions:
- Preliminary reference values for serum ACE activity in healthy Spanish individuals, stratified by ACE I/D genotype, have been established.
- Significant variations in ACE activity and its reference intervals exist across different ACE genotypes.
- These genotype-specific reference values can enhance the clinical utility of ACE activity measurements.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...